ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Gramicidin

Its studies are mostly in Pharyngitis, led by Valenta Pharm JSC.

Furthest: phase 2, since Feb 17, 20251 company-led study, 1 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Valenta Pharm JSC11 open or runningphase 2since Feb 17, 2025Feb 17, 2025Dec 31, 2026phase 2 · NCT06843018

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 17, 2025First study: phase 2 study in PharyngitisFirst studyNCT06843018 · 300 planned · Russia

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in PharyngitisNCT06843018

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Cell membrane inhibitor”ChEMBL 37, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06843018Pharyngitis · Russia2RecruitingDec 31, 2026300

How it is read

Names in the registry

  • “Grammidin with anesthetic”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.